Market Report, "Nigeria Pharmaceuticals & Healthcare Report Q2 2011", published

Feb. 23, 2011 - PRLog -- Q211 has proved to be a difficult period for Nigeria's Pharmaceutical market. In December 2010, leaked US embassy cables indicated that Pfizer, the world's largest pharmaceutical manufacturer, had hired investigators to unearth evidence of corruption against the Nigerian attorney general. Action taken by the company was alleged to have stemmed from a desire to persuade him to drop legal action over a controversial drug trial involving the antibiotic Trovan (trovafloxacin) in 1996 for treating children with meningitis. The subsequent public outcry from these revelations has hurt Pfizer's public image in Nigeria. This is likely to impact the company's sales in the short term and slow the approval process for new products from multinational drugmakers.

Also in December, Edo State government began the construction of a modern hospital ward at Edo State Specialist hospital in Nigeria, while November 2010 saw construction begin for a multi-billion naira healthcare facility in Kano State, primarily paid for with the money from the 2009 Pfizer lawsuit settlement.

In January 2011, the Nigerian Medical Association (NMA)'s Ebonyi State chapter began an indefinite strike, saying the action was a result of the government's refusal to pay the consolidated medical salary structure (CONMESS) to doctors. Physicians argue that an increase in wages is needed to stem physician emigration to developed countries. In November 2010, the governor of Nigeria's Niger State increased the wages of healthcare workers by 180% in an effort to retain more staff.

In December 2010, Karniyus Gamaniel, director of the Nigerian Institute of Pharmaceutical Research and Development (NIPRD), announced that production of the phytogenic (plant-derived) sickle cell disease (SCD) drug Nicosan (an ethanol/water extract of Piper guineense seeds, Pterocarpus osum stem, Eugenia caryophyllus fruit and Sorghum bicolor leaves) is to resume. The production and phase III trials of the drug were stopped when the government withdrew Xechem Pharmaceuticals Nigeria's production licence in 2009, following accusations of misuse of funds.

Over 200,000 children are born with SCD in sub-Saharan Africa every year and there are an estimated 4mn people in Nigeria with some form of the disease, according to AesRx, a company developing SCD treatment Aes-103 (5-hydroxymethyl-2-furfural). Currently, the main treatment for SCD is Droxia (hydroxyurea), which was approved in 1998. However, not all patients respond to this drug and some experience adverse effects, including myelosuppression (suppression of the body's production of bone marrow). This lack of available drugs presents an opportunity to drugmakers, especially as the World Health Organization (WHO) has granted almost every SCD drug orphan status to help address the immediate healthcare need.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/126902_nigeria_pharmaceuticals...


Partial Table of Contents:

SWOT Analysis
- Nigeria Pharmaceuticals And Healthcare Industry SWOT
- Nigeria Political SWOT
- Nigeria Economic SWOT
- Nigeria Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings, Q111
- Rewards
- Risks
Nigeria - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Drugs
- Recent Developments in Regards to Counterfeit Drugs
- Pricing And Reimbursement Regime
Industry Developments
- Epidemiology
- Maternal and Child Health
- Non-communicable diseases
- Communicable Diseases
- HIV/AIDS
- Recent Infectious Diseases Developments
- Healthcare Financing
- Healthcare Provision
- Recent Healthcare Sector Developments
- Healthcare Reforms
- Health Insurance
- Table: Nigeria's National Health Insurance Scheme (NHIS) Key Facts
- Traditional African Medicine
- National Drug Policy
- Pharmaceutical Distribution
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecasts
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Nigeria - Macroeconomic Forecasts
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Export & Import Indicators 2007-2015
- Medical Devices Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Recent Developments In The Medical Devices Market
- Table: Nigeria Free Zones: Key Incentives
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecasts
Competitive Landscape
- Pharmaceutical Industry
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1269...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.